Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals

BioImpacts

Volumn 3, Issue 3, 2013, Pages 105-109

  Barar, Jaleh ^a   Omidi, Yadollah ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Gene delivery; Gene therapy; Genotoxicity; Microarray; Nanotoxicology; Toxicogenomics

Indexed keywords

NANOCARRIER; NANOMATERIAL; NUCLEIC ACID; POLYCATION; POLYETHYLENEIMINE; POLYGLACTIN;

ARTICLE; BIOLOGICAL ACTIVITY; CYTOTOXICITY; DNA DAMAGE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE THERAPY; GENE VECTOR; GENOTOXICITY; LIPOSOMAL GENE DELIVERY SYSTEM; MICROARRAY ANALYSIS; MUTAGENICITY; NANOANALYSIS; NANOTOXICOLOGY; NONVIRAL GENE DELIVERY SYSTEM; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STRUCTURE ANALYSIS; SURFACE CHARGE; TARGET CELL; TOXICOGENETICS;

EID: 84887341756     PISSN: 22285652     EISSN: 22285660     Source Type: Journal    
DOI: 10.5681/bi.2013.028     Document Type: Article

References (51)

1. Rubanyi GM. The future of human gene therapy. Mol Aspects Med 2001;22:113-42.
2. Barar J, Omidi Y. Translational Approaches toward Cancer Gene Therapy: Hurdles and Hopes. BioImpacts 2012;2:127-43.
3. Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001;6:303-15.
4. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000;1:91-9.
5. Kerr D. Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer 2003;3:615-22.
6. Mcmanus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-47.
7. Cristiano RJ. Viral and non-viral vectors for cancer gene therapy. Anticancer Res 1998;18:3241-5.
8. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001;38:177-92.
9. Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003;177:437-47.
10. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002;9:1647-52.
11. Tamura T, Sakata T. Application of in vivo electroporation to cancer gene therapy. Curr Gene Ther 2003;3:59-64.
12. Dass CR. Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo. J Pharm Pharmacol 2002;54:593-601.
13. Audouy SA, de Leij LF, Hoekstra D, Molema G. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 2002;19:1599-605.
14. Ferber D. Gene therapy. Safer and virus-free? Science 2001;294:1638-42.
15. Ferber D. Gene therapy. Repair kits for faulty genes. Science 2001;294:1639.
16. Clark PR, Hersh EM. Cationic lipid-mediated gene transfer: current concepts. Curr Opin Mol Ther 1999;1:158-76.
17. Hirko A, Tang F, Hughes JA. Cationic lipid vectors for plasmid DNA delivery. Curr Med Chem 2003;10:1185-93.
18. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002;54:715-58.
19. Aissaoui A, Oudrhiri N, Petit L, Hauchecorne M, Kan E, Sainlos M, et al. Progress in gene delivery by cationic lipids: guanidinium-cholesterol-based systems as an example. Curr Drug Targets 2002;3:1-16.
20. Ellinger-Ziegelbauer H, Aubrecht J, Kleinjans JC, Ahr HJ. Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity. Toxicol Lett 2009;186:36-44.
21. Aubrecht J, Caba E. Gene expression profile analysis: an emerging approach to investigate mechanisms of genotoxicity. Pharmacogenomics 2005;6:419-28.
22. Ramskold D, Kavak E, Sandberg R. How to analyze gene expression using RNA-sequencing data. Methods Mol Biol 2012;802:259-74.
23. Saei AA, Omidi Y. A glance at DNA microarray technology and applications. BioImpacts 2011;1:75-86.
24. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70.
25. Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari CA. Microarrays and toxicology: the advent of toxicogenomics. Mol Carcinog 1999;24:153-9.
26. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target 2003;11:311-23.
27. Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr Drug Deliv 2005;2:429-41.
28. Hollins AJ, Omidi Y, Benter IF, Akhtar S. Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. JDrug Target 2007;15:83-8.
29. Omidi Y, Kafil V, Barar J. Toxicogenomics of nonviral cationic gene delivery nanosystems. In: Yuan X, editor. Nonviral gene therapy. Rijeka: InTech; 2011. p. 547-76.
30. Najar AG, Pashaei-Asl R, Omidi Y, Farajnia S, Nourazarian AR. EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. Asian Pac J Cancer Prev 2013;14:495-8.
31. Nourazarian AR, Najar AG, Farajnia S, Khosroushahi AY, Pashaei-Asl R, Omidi Y. Combined EGFR and c-Src antisense oligodeoxynucleotides encapsulated with PAMAM Denderimers inhibit HT-29 colon cancer cell proliferation. Asian Pac J Cancer Prev 2012;13:4751-6.
32. Nourazarian AR, Pashaei-Asl R, Omidi Y, Najar AG. c-Src antisense complexed with PAMAM denderimes decreases of c-Src expression and EGFR-dependent downstream genes in the human HT-29 colon cancer cell line. Asian Pac J Cancer Prev 2012;13:2235-40.
33. Fox S, Hollins A, Sohail M, Omidi Y, Southern E, Benboubetra M, et al. The design and activity of small interfering RNA (siRNA) as a potential therapeutic agent for the down-regulation of the epidermal growth factor receptor (EGFR). J Pharm Pharmacol 2004;56:28.
34. Hollins A, Omidi Y, Fox S, Griffiths S, Akhtar S. Polyethylenimine-mediated delivery of small interfering RNA targeting the epidermal growth factor receptor: a comparison of linear and branched polymer architecture. J Pharm Pharmacol 2004; 56: 53.
35. Hollins AJ, Benboubetra M, Omidi Y, Zinselmeyer BH, Schatzlein AG, Uchegbu IF, et al. Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor. Pharm Res 2004;21:458-66.
36. Omidi Y, Benboubetra M, Hollins A, Drayton R, Akhtar S. Dendrimeric delivery systems for siRNA and gene therapy intrinsically alter gene expression in human epithelial cells. J Pharm Pharmacol 2004; 56: 52.
37. Omidi Y, Barar J, Heidari HR, Ahmadian S, Yazdi HA, Akhtar S. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial a549 cells. Toxicol Mech Methods 2008;18:369-78.
38. Barar J, Hamzeiy H, Mortazavi-Tabatabaei SA, Hashemi-Aghdam SE, Omidi Y. Genomic signature and toxicogenomics comparison of polycationic gene delivery nanosystems in human alveolar epithelial A549 cells. Daru 2009;17:139-47.
39. Barar J, Omidi Y. Cellular Trafficking and Subcellular Interactions of Cationic Gene Delivery Nanomaterials. J Pharm Nut Sci 2011;1:68-81.
40. Kafil V, Omidi Y. Cytotoxic impacts of linear and branched polyethylenimine nanostructures in A431 cells. BioImpacts 2011;1:23-30.
41. Omidi Y, Barar J. Induction of human alveolar epithelial cell growth factor receptors by dendrimeric nanostructures. Int J Toxicol 2009;28:113-22.
42. Pedroso de Lima MC, Simoes S, Pires P, Faneca H, Duzgunes N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Deliv Rev 2001;47:277-94.
43. Bell H, Kimber WL, Li M, Whittle IR. Liposomal transfection efficiency and toxicity on glioma cell lines: in vitro and in vivo studies. Neuroreport 1998;9:793-8.
44. Benns JM, Mahato RI, Kim SW. Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine. J Control Release 2002;79:255-69.
45. Romoren K, Thu BJ, Bols NC, Evensen O. Transfection efficiency and cytotoxicity of cationic liposomes in salmonid cell lines of hepatocyte and macrophage origin. Biochim Biophys Acta 2004;1663:127-34.
46. Bragonzi A, Conese M. Non-viral approach toward gene therapy of cystic fibrosis lung disease. Curr Gene Ther 2002;2:295-305.
47. Schatzlein AG. Non-viral vectors in cancer gene therapy: principles and progress. Anti-Cancer Drugs 2001;12:275-304.
48. Tranchant I, Thompson B, Nicolazzi C, Mignet N, Scherman D. Physicochemical optimisation of plasmid delivery by cationic lipids. J Gene Med 2004; 6 Suppl 1:S24-35.
49. Omidi Y, Davaran S. Impacts of biodegradable polymers: Towards biomedical applications. In: Sharma SK, Mudhoo A, editors. Handbook of applied biopolymer technology: Synthesis, degradation and applications. Cambridge: Royal Society of Chemistry; 2011. p. 388-418.
50. Omidi Y, Hollins AJ, Drayton RM, Akhtar S. Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J Drug Target 2005;13:431-43.
51. Verma IM. Gene therapy: hopes, hypes, and hurdles. Mol Med 1994;1:2-3.